Calls for papers
-
Fresenius Kabi has announced the availability of 30 ml vials acetylcysteine inhalation solution, 20%, helping to alleviate a shortage of the product in the US. The company is marketing the inhalation solution in the US… Read more . . .
-
As expected, the European Commission has approved Novartis’s Seebri Breezhaler glycopyrronium bromide DPI for the treatment of COPD. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive recommendation for… Read more . . .
-
MicroDose Therapeutx has completed the Phase 1 clinical program for its inhaled antiviral fusion inhibitor MDT-637 for the treatment of respiratory syncytial virus infection and plans to present data from the three studies at the… Read more . . .
-
The Japanese Ministry of Health, Labor and Welfare (MHLW) has approved Novartis’s Seebri glycopyrronium bromide inhalation capsules, delivered by the Breezhaler DPI, for the treatment of COPD. The product should be available in Japan by… Read more . . .
-
ABC Laboratories, Columbia, MO. The Senior Scientist / Team Leader is a results-oriented, problem-solver and laboratory supervisor who will support ABC Inhalation Product Development programs. Experience with pMDI, DPI and nasal/pulmonary delivery systems is required.… Read more . . .
-
ABC Laboratories, Columbia, MO. The Principal Scientist/Team Leader is a results-oriented, problem-solver and laboratory supervisor who will support ABC Inhalation Product Development programs. Experience with pMDI, DPI and nasal/pulmonary delivery systems is required. Direct hands-on… Read more . . .
-
The British Pharmacopoeia (BP) Inhaled Products Working Party has published its recommendations for BP monographs for inhalation as of September 17, 2012. According to the document, “Safety and efficacy are critical considerations; the Working Party… Read more . . .
-
GlaxoSmithKline says that it submitted a Japanese New Drug Application (JNDA) for its fluticasone furoate (FF)/vilanterol(VI) dry powder inhaler for the treatment of COPD and asthma on September 25, 2012. The FF/VI combination will be… Read more . . .
-
Hovione has announced the addition of services for crystal design, particle size reduction to the micro or nano-scale, and amorphous solid dispersions. The company, which provides particle engineering, formulation development, and clinical manufacture to Phase… Read more . . .
-
The US Patent and Trade Office has awarded Aegis Therapeutics US Patent No. 8,268,791 for “Alkylglycoside compositions for drug administration.” The company is highlighting the patent’s coverage of fast-acting intranasal triptan formulations for the treatment… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland